You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海創藥業(688302.SH):HP530S片擬用於實體瘤臨牀試驗申請獲得受理
格隆匯 02-09 16:45

格隆匯2月9日丨海創藥業(688302.SH)公佈,公司收到國家藥品監督管理局核准簽發的《受理通知書》,HP530S片擬用於實體瘤的臨牀試驗申請獲得受理。

HP530S片是公司自主研發的具有高活性及高選擇性的黏着斑激酶(Focal adhesionkinase,FAK)抑制劑。通過抑制FAK調節其下游信號通路,從而達到抑制腫瘤細胞的轉移、增殖和血管生成等作用。臨牀擬用於實體瘤。根據我國新化學藥品註冊分類規定,其藥品註冊分類為化藥1類。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account